Century Therapeutics (IPSC) vs ProQR Therapeutics N.V. (PRQR)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Century Therapeutics (IPSC) has outperformed ProQR Therapeutics N.V. (PRQR) over the past year, gaining 129.0% versus a loss of 28.2%. Over five years, PRQR leads with a -79.3% price change compared with -93.4% for IPSC. Century Therapeutics is the larger company by market cap ($231.8 million vs $230.0 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IPSC | PRQR |
|---|---|---|
| Share price | $1.28 | $1.63 |
| Market cap | $231.78M | $230.02M |
| 1-day change | -3.03% | -1.21% |
| YTD return | +28.64% | -19.31% |
| 1-year return | +128.98% | -28.19% |
| 5-year return | -93.37% | -79.31% |
| EPS (TTM) | $-0.93 | $-0.45 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $3.04 | $3.10 |
| 52-week low | $0.435 | $1.33 |
| Distance from 52-week high | -57.89% | -47.42% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +271.09% | +377.30% |
| Average volume | 658.60K | 814.69K |
| Shares outstanding | 181.08M | 141.12M |
| Employees | 78 | 186 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed PRQR by 157.2 percentage points over the past year.
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
About ProQR Therapeutics N.V.
PRQR stock →ProQR Therapeutics N.V., a clinical-stage biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company develops an RNA editing platform through its Axiomer RNA editing technology for genetic disorders with unmet needs.
Health Care · Biotechnology: Pharmaceutical Preparations · 186 employees
IPSC vs PRQR FAQ
Which is bigger, Century Therapeutics or ProQR Therapeutics N.V.?
Century Therapeutics (IPSC) is larger, with a market capitalization of $231.78M compared with $230.02M for ProQR Therapeutics N.V. (PRQR).
Which stock has performed better over the past year, IPSC or PRQR?
IPSC returned +128.98% over the past 12 months, compared with -28.19% for PRQR (price return, excluding dividends). Past performance does not predict future results.
Are Century Therapeutics and ProQR Therapeutics N.V. in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Century Therapeutics and Biotechnology: Pharmaceutical Preparations for ProQR Therapeutics N.V..